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Left ventricular dysfunctionObjective:Red-cell distributionwidth (RDW)has been identiﬁed as a novel prognosticmarker in a heterogeneous
group of heart failure patients. In this group, diastolic dysfunction is associated with worse outcome. As the
evidence is limited, the aim of the present study was to assess the relationship of RDW to diastolic markers in
patients with left ventricular dysfunction (LVD) diagnosed during cardiac catheterization.
Methods: Clinical and angiographic datawere collected retrospectively on a total of 291 stable patients (mean age
62 years, 199 males) with systolic dysfunction documented during cardiac catheterization in a regional medical
center between January 2006 and December 2010.
Results: Positive associationwas seen between RDWand Left ventricular end diastolic pressure (LVEDP), estimat-
ed systolic pulmonary arterial pressure(sPAP), and left atrial dimension (LAD) (r: 0.18, 0.24, 0.28, respectively;
p:b0.05).Three year retrospective survival analysis for 108 patients admitted in the ﬁrst 2 years showed a
statistically signiﬁcant decrease in survival patients with high RDW(N14.5) vs. normal RDW (73%vs.88%;log
rank p:0.03). This was seen even in the asymptomatic subgroup (71% vs. 94%; log rank p: 0.01).
Conclusion: RDW correlates with markers of diastolic dysfunction in patients with LVD. Additionally, in patients
asymptomatic LVD, high RDW is still associated with lower survival.
Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Red cell distribution width (RDW) is a readily available test from a
standard full blood count, and is a measure of variation in red blood
cell size. It has been shown in many studies to be a powerful predictor
of outcome in heart failure patients [1–3].Most of these studies enrolled
patients with congestive symptoms and some included patients with
preserved systolic function. Among other predictors of worse outcome
in heart failure population is the presence of diastolic dysfunction [4,
5]. In this work, we sought to study the correlation between RDW and
markers of diastolic dysfunction in patients with symptomatic and
asymptomatic LVD.2. Methods
Medical and angiographic records of patients who underwent elec-
tive cardiac catheterization in a 500-bed teaching community hospital
in urban New Jersey from January 2006 to December 2010 were.
en access article under the CC BY-NCretrospectively reviewed. Patients with normal EF on left ventri-
culogram, iron deﬁciency anemia, positive hemoccult blood,Hemoglobin
b10 g/dL, cancer, AIDS, elevated tropinins, or stage III-V chronic kidney
disease were excluded. Data regarding estimated ejection fraction (EF),
number of diseased vessels, and Left ventricular end diastolic pressure
(LVEDP) were retrieved from cardiac catheterization reports. If right
heart catheterization was not performed, systolic pulmonary artery
pressurewas estimated using tricuspid regurgitation velocity, in addition
to estimated right atrial pressure from transthoracic echocardiography in
the same admission. Echocardiography reports were also used to assess
chamber dimension and size. Other demographic and clinical data
were collected from the electronic medical records of those patients.
All-cause mortality data were obtained from social security death index
for patients in the ﬁrst 2 years of the study to calculate the 3 year
retrospective survival analysis. The study was conducted in Trinitas
Regional Medical Center, where it was approved by the Institutional
Review Board.
Highest RDW and brain natriuretic peptide (BNP) results during the
index admission were recorded. Patients were considered to have
symptomatic LVD if they were known to have symptoms and signs of
heart failure at, or before the time of catheterization. Non-ischemic car-
diomyopathy (NICD) was deﬁned as the presence of LVD with no-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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or their major branches.
3. Statistical analysis
Interval variables were tested for normality using the D'Agostino-
Pearson omnibus normality test. Groupwise comparisons for normally
distributed variables were made using Student's t test; variables that
were not normally distributed were subjected to a nonparametric
(Mann–Whitney) test. For non-normally distributed data, medians
and interquartile ranges (IRs) are provided; for normally distributed
variables, data are expressed as means and standard deviations (SDs).
Categorical data were compared using Fisher's exact test. Odds Ratios
(OR) and 95% conﬁdence intervals (CIs) are provided. Spearman's
rank correlation coefﬁcient was used to measure the statistical associa-
tion between two non-normally distributed variables. Logistic regres-
sion was used to adjust ORs for differences in baseline characteristics
if the P value for the difference between the groups was less than
0.05. For the present study, α was set at 0.05; thus, P b 0.05 (two-
sided) was considered to be statistically signiﬁcant. Data were analyzed
using Prism software (GraphPad Corp, USA), except for logistic regres-
sion, which was performed using an online routine (available at www.
stat-pages.org/logistic.html; accessed on July, 14, 2011). Retrospective
survival analysis was done using Kaplan–Meier curvewith log rank test.
4. Results
We reviewed the angiographic reports of 2150 patients, of them 291
patients were included (199men,mean age 61.9± 13.5 yr). This cohort
was divided into 2 groups, Group 1 (patients with high RDW) included
117 patients, and Group 2 (normal RDW group) included 174 patients
(Table 1). Ischemic cardiomyopathy (ICD) was found in 169 patients,
and non-ischemic cardiomyopathy (NICD) was found in the remaining
122 patients. Symptomatic LVD was found in 41% of the group. Patients
with high RDWwere more likely to be symptomatic (OR 4.5 (2.7–7.4;
p: b0.0001)), more likely to have non- ischemic cardiomyopathy (OR:
2.9 (1.8–4.7; p: b0.0001)).They weremore likely to have lower EF (me-
dian EF 35% (IR: 25–40%) vs. normal RDWmedian EF 40% (IR 30–45%);Table 1
Abbreviations: ACEi/ABR blockers: angiotensin converting enzyme inhibitors/angiotensin
receptor blockers; BMI: bodymass index; BNP: brain natriuretic peptide; BUN: blood urea
nitrogen; Cr: creatinine; Hb: hemoglobin, Na: serum sodium.
Group 1 (RDW N 14.5%)
117 patients
Group 2 (RDW ≤ 14.5%)
174 patients
P value
Age (mean) 61 ± 13 years 62 ± 14 years 0.6
Male gender 79 120 0.8
Race b0.0001
Caucasians 38 (33%) 75(43%)
Hispanics 23 (20%) 60 (35%)
Blacks 56 (47%) 39(22%)
Diabetes 49 71 0.9
Hypertension 94 122 0.06
Dyslipidemia 55 80 0.9
Smoking 57 70 0.16
BMI (kg/m2) 28 (25–32) 28 (25–32) 0.4
Symptoms of CHF 73 47 b0.0001
Atrial ﬁbrillation 25 22 0.08
Cr (mg/dl) 0.9 (0.8–1.1) mg/dl 1.1 (0.9–1.3) mg/dl b0.0001
BUN (mg/dl) 14 (11–18) 16 (12–24) 0.005
Na (meq/dl) 137 (136–140) meq/dl 137(136–140) 0.38
BNP (pg/ml) 907 (252–1923) 348 (128–676) b0.0001
Hb (gm/dl) 13.3 (12.3–14.2) 14 (12.7–14.9) 0.003
Medications
Beta blockers 52 76 0.9
ACEi./ARB Blockers 70 75 0.006
Statins 41 65 0.7
Diuretics 41 48 0.07
Digoxin 17 9 0.005
warfarin 11 11 0.3p:0.0007), higher BNP (median BNP: 907 pg/ml (IR: 253–1923)
vs.347 pg/ml (IR: 127–676); p: b0.0001), larger LAD (median LAD
4.17 cm (3.65–4.80) vs. normal RDW median LAD 3.78 cm (IR:
3.38–4.2); p: b0.0001).There was also a trend toward having more
atrial ﬁbrillation in group 1 vs. group 2 (OR: 1.9 (1.01–3.06); p: 0.08),
and larger left ventricular end diastolic volume index(LVEDVI) (68 ml/m2
in group 1 vs. 61 ml/m2 in group 2; p: 0.05). Differences in LVEDP
did not reach statistical signiﬁcance (group 1 LVEDP 18 vs. 16 mm Hg in
group 2, p: 0.09) (Table 2). In the symptomatic group, patients who had
high RDWwere more likely to have abnormal maximum left ventricular
dP/dt (OR: 6 (1.3–28); p: 0.04). NICD patients were more likely to have
abnormal RDW in comparison to ICD patients (OR: 2.9 (1.783–4.715);
p: b0.001). This was independent of the presence of symptoms, or
severe LVD (EF b 30%) (p value for interaction N0.05).In this study,
Hypertension was the presumed etiology in 67% of NICD patients. The
latter group were relatively younger than ICD patients (median age
57 yr. (47–68) vs ICD 65 yr. (54–75)),they were less likely to be on
statins(OR: 0.4 (0.24–0.68); p: 0.005), and they were found to have
larger ventricles(median LVEDVI 74 ml/m2 vs. 64 ml/m2; p: 0.006).
In addition to the well-established correlation between RDW and
MCV, creatinine, BUN, EF, we found amodest but statistically signiﬁcant
correlations between RDW and LAD (r: 0.28; p: b0.0001), sPAP(r: 0.24;
p: 0.0028), LVEDP (r: 0.18; p: 0.039), and BNP (r: 0.3; p: b0.0001)
(Table 3, Figs. 1, 2, and 3).
Data for 108 patients (52 patients asymptomatic) from the period
(Jan 2006 to Dec. 2007) were included in 3-year retrospective survival
analysis, and they were divided according to RDW into 2 groups.
Three year survival was higher in the patients with LVD and normal
RDW vs. high RDW (88% vs. 73%; log rank p: 0.03) (Fig. 4).This was
also seen even in the asymptomatic patients (normal RDW group 94%
vs. high RDW group 71%; log rank p: 0.01) (Fig. 5).Survival curves
were not different in the symptomatic group between high and normal
RDW group (log rank p: N0.05).
5. Discussion
High RDW values have been shown to be independently related to
increasedmortality and cardiovascular events in peoplewith congestive
heart failure [1–3], acute coronary syndrome [6,7], and in patients
referred for coronary angiography [8]. This study extends the prognostic
value of RDW to all patients with systolic LVD even the asymptomatic
group, a group that is less presented in other studies.
As this correlation was independent of hemoglobin level in most of
the studies [1–4,9], RDW is presumed to reﬂect the degree of neurohor-
monal activation in HF patients [10,11]. Not surprising was our ﬁnding
that RDW correlates with BUN and BNP, two other markers of neuro-
hormonal activation [12].Table 2
Abbreviations: L. A.: left atrium; LVEDP: left ventricular end diastolic volume; LVEDVI: left
ventricular end diastolic volume index; LVIDd: left ventricular internal dimension in diastole,
LVIDs: left ventricular internal dimension in sytole; sPAP: systolic pulmonary artery pressure.
Group1 Group 2 P value
Ejection fraction 35%(25–40) 40% (30–45) 0.0007
Diseased vessels b0.0001
None 67(57%) 55 (31%)
Single vessel 15 (13%) 39 (22%)
Two vessels 20 (17%) 31 (18%)
Three vessels 15 (13%) 49 (29%)
LVEDP (mm Hg) 18 (12–25) 16 (11–21) 0.09
Maximum LV dP/dt
(mm Hg/s)
1171 (965–1471) 1340 (1109–1564) 0.2
L.A. Dimension(cm) 3.8 (3.4–4.2) 4.2 (3.7–4.8) b0.0001
LVEDVI (ml/m2) 68 (53–86) 62 (50–77) 0.05
LVIDd (cm) 5.4 (4.9–6.3) 5.6 (4.9–6.3) 0.7
LVIDs(cm) 4.1(3.6–5) 3.9(3.5–4.8) 0.4
Estimated sPAP (mm Hg) 27 (16–46) 21(15–29) 0.009
Table 3
Abbreviations: LVEDP: left ventricular end diastolic pressure; sPAP: systolic pulmonary
artery pressure.
The biomarker Correlation factor (r) P value
Blood urea nitrogen 0.2 0.0006
Serum creatinine 0.25 b0.0001
BNP 0.3 b0.0001
Hemoglobin −0.17 0.003
Mean corpuscular volume −0.2 0.0002
Ejection fraction −0.25 b0.0001
Left atrial dimension 0.28 b0.0001
Estimated sPAP 0.24 b0.003
LVEDP 0.13 0.04
Fig. 2. The correlation between RDW and estimated systolic pulmonary artery pressure
(sPAP).
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Chronic longstanding diastolic dysfunction leads to left atrial dilation
and increase in pulmonary circulation pressure. Brucks et al. proved
that in patients who had systolic HF, the degree of diastolic dysfunction
inﬂuenced survival rate (OR 1.64, p b 0.05), whereas EF and LVEDVI did
not. Diastolic dysfunction was a better predictor of B-type natriuretic
peptide levels and mortality than ejection fraction or LVEDVI [4]. In
the aforementioned study, BNP correlates with diastolic dysfunction
but not with EF. Here in this work, RDW correlates with both systolic
(EF) and diastolic measures of left ventricular function. This result
comes in agreementwith a previous study of acute heart failure patients
from South Korea where a value of RDW N13.45% was predictive for
early mitral inﬂow velocity to early diastolic mitral annular velocity
(E/E′) N 15 in echocardiography, suggesting elevated LVEDP [13]. The
association between RDW and LAD helps explain the trend toward
more atrial ﬁbrillation in patients with high RDW in our cohort and in
previous studies in heart failure patients [1,14].
In our group we found a positive correlation between sPAP and
RDW. Although we attribute this to diastolic dysfunction, other mecha-
nismsmay play a role as recent studies have shown that RDW is a prog-
nostic factor in patients with primary pulmonary hypertension [15].
NICD patients were more likely to have high RDW than ICD in our
cohort despite being younger patients. This was independent of symp-
toms, and severe LVD (EF b 30%). A closer look at this group reveals
that most of them have LVD due to hypertension. Studies on left ventri-
cle systolic function in hypertensive patients indicate that only about 1/6
of hypertensive patients with left ventricular hypertrophy (LVH)
present with systolic dysfunction. If hypertension is not controlled, the
modiﬁcations of left ventricle will progressively increase, leading to LVFig. 1. The correlation between RDW and left atrial dimension (L.A.).dilation which seems to herald the transition to heart failure [16].
Because NICD group had larger ventricles (expressed as LEDVI) than
ICD, we think that they represented a more advanced stage of LVD in
poorly treated and probably noncompliant patients. In recent papers
the transition from LVH to CHF has been related to a marked increase
in myocardial expression of growth factor TGF beta 1, which inﬂuences
interstitial ﬁbrosis, and stimulation of apoptosis by myocardial expres-
sion of tumor necrosis factor alpha and the subsequent increase in in-
ducible NO-synthase and oxidative stress [16]. We speculate that these
humeral factors affect the bone marrow adversely, and are suppressed
by statins which were used more often in our ICD patients, and which
were found in other studies to be associated with lower RDW [2,8].
Knowing that BNP was used in previous studies to screen hyperten-
sive patients for systolic and diastolic dysfunction [17–19], it would be
prudent to consider looking for these complications in non-anemic
patients with poorly controlled hypertension and high RDW.
Our study suffers from the limitations of retrospective design, lack
of detailed echocardiographc data like left atrial volume, and diastolic
dysfunction grading by echocardiography. Also, the small number of
patients available in the ﬁrst 2 years for retrospective survival analysis
has limited our capability to draw any valid conclusion from the nega-
tive results.Fig. 3. Correlation between RDW and left ventricular end diastolic pressure (LVEDP).
Fig. 4. Kaplan–Meier curves for all-cause mortality in all patients with left ventricular
dysfunction (LVD) based on their RDW.
Fig. 5. Kaplan–Meier curves for all-cause mortality in patients with asymptomatic left
ventricular dysfunction (LVD) based on their RDW.
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RDW correlates with markers of diastolic dysfunction in patients
with LVD, and high values were associated with lower survival even in
asymptomatic patients.
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